Q2 Earnings Forecast for Envista Issued By Leerink Partnrs

Envista Holdings Corporation (NYSE:NVST) – Research analysts at Leerink Partnrs boosted their Q2 2025 earnings per share (EPS) estimates for Envista in a research report issued to clients and investors on Monday, July 14th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.23 per share for the quarter, up from their prior forecast of $0.22. The consensus estimate for Envista’s current full-year earnings is $1.00 per share. Leerink Partnrs also issued estimates for Envista’s Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $1.00 EPS, FY2026 earnings at $1.13 EPS and FY2027 earnings at $1.33 EPS.

NVST has been the subject of several other research reports. Piper Sandler dropped their price objective on shares of Envista from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, April 30th. UBS Group dropped their price target on Envista from $21.00 to $18.00 and set a “neutral” rating for the company in a research report on Monday, May 5th. Evercore ISI lifted their price objective on Envista from $19.00 to $23.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 9th. Baird R W upgraded Envista from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 27th. Finally, Robert W. Baird upgraded Envista from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $21.00 to $23.00 in a report on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $20.23.

Envista Trading Down 0.6%

Shares of NVST opened at $19.70 on Wednesday. The firm’s fifty day moving average is $18.83 and its two-hundred day moving average is $18.53. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.43. The stock has a market cap of $3.34 billion, a PE ratio of -3.02, a price-to-earnings-growth ratio of 1.25 and a beta of 1.00. Envista has a 52-week low of $14.22 and a 52-week high of $23.00.

Envista (NYSE:NVST) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.20 by $0.04. Envista had a positive return on equity of 4.07% and a negative net margin of 44.90%. The firm had revenue of $616.90 million during the quarter, compared to analysts’ expectations of $608.17 million. During the same period in the previous year, the business earned $0.26 earnings per share. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis.

Institutional Trading of Envista

Hedge funds and other institutional investors have recently modified their holdings of the business. UMB Bank n.a. raised its position in Envista by 214.4% in the first quarter. UMB Bank n.a. now owns 2,094 shares of the company’s stock valued at $36,000 after purchasing an additional 1,428 shares during the period. Parallel Advisors LLC grew its stake in shares of Envista by 100.1% in the second quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock valued at $55,000 after buying an additional 1,397 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp purchased a new stake in shares of Envista in the 4th quarter valued at $86,000. Palouse Capital Management Inc. lifted its stake in Envista by 14.4% during the 1st quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company’s stock worth $163,000 after acquiring an additional 1,186 shares in the last quarter. Finally, FourThought Financial Partners LLC acquired a new position in Envista during the 1st quarter worth about $180,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.